Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 1;155(8):968-971.
doi: 10.1001/jamadermatol.2019.0369.

Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response

Lu Chen  1   2 , Kenneth R Carson  3   4   5 , Karl W Staser  1 , Neha Mehta-Shah  3 , András Schaffer  6   7 , Ilana S Rosman  1   6 , Amy Musiek  1
Affiliations

Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response

Lu Chen et al. JAMA Dermatol. .

Abstract

This case series report of mogamulizumab-associated cutaneous granulomatous drug eruption (CGDE) describes 12 patients with mycosis fungoides (MF) whose CGDE mimicked the MF but was followed by durable clinical MF response.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Carson is employed by Flatiron Health and received consultancy fees from Roche; he also reports grants from Kyowa Hakko Kirin and personal fees from Flatiron Health and Roche outside the submitted work. Dr Mehta-Shah received research support from Celgene, Verastem, Bristol-Myers Squibb, and Genentech and consultancy fees from Spectrum; she also reports personal fees from Kyowa Hakko Kirin outside the submitted work. Dr Schaffer received personal fees and honoraria from Wolters Kluwer for his textbook Hematopathology of the Skin. Dr Musiek served as an investigator for Actelion Pharmaceuticals, Kyowa Hakko Kirin, and Soligenix and as an advisory board member for Actelion Pharmaceuticals, Kyowa Hakko Kirin, and Seattle Genetics; she also reports other associations and personal fees from Kyowa Hakko Kirin during the conduct of the study as well as other associations with Elorac, miRagen, Soligenix, and personal fees from Seattle Genetics and Actelion outside the submitted work. While Dr Musiek was an investigator for Kyowa Hakko Kirin for the MAVORIC trial, the observations reported herein were made independently of Kyowa Hakko Kirin and first noticed only during weekly clinicopathological conferences with dermatologic, oncologic, and dermatopathologic colleagues. No other disclosures were reported.

Figures

Figure.
Figure.. Physical and Histologic Findings of Mogamulizumab-Associated CGDE
A and B, Representative cutaneous lesions from the trunk of patient 2 are shown. Mogamulizumab-associated cutaneous granulomatous drug eruption (CGDE) presents as erythematous macules and patches (A) evolving into scaly erythematous plaques (B). C and D, All skin biopsies demonstrated granulomatous infiltrates with epithelioid histiocytes forming superficial perivascular granulomata (C) and in many cases deep granulomata with multinucleated giant cells and eosinophils (D) under hematoxylin-eosin staining. The histopathologic images were captured from lesional skin biopsies of patients 3 (C) and 2 (D) using a Leica DM 2500 microscope, Leica MC170HD camera, and Leica Application Suite, version 4.2.
See this image and copyright information in PMC

References

    1. Kim YH, Bagot M, Pinter-Brown L, et al. ; MAVORIC Investigators . Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204. doi:10.1016/S1470-2045(18)30379-6 - DOI - PubMed
    1. Olsen EA, Whittaker S, Kim YH, et al. ; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer . Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598-2607. doi:10.1200/JCO.2010.32.0630 - DOI - PMC - PubMed
    1. Hsi AC, Lee SJ, Rosman IS, et al. . Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implications. J Am Acad Dermatol. 2015;72(1):159-167. doi:10.1016/j.jaad.2014.09.022 - DOI - PubMed
    1. Wanat KA, Rosenbach M, Zoiber AF, Zhang PJ, Schaffer A. E-cadherin is expressed by mono- and multinucleated histiocytes in cutaneous sarcoidal and foreign body granulomas. Am J Dermatopathol. 2014;36(8):651-654. doi:10.1097/DAD.0b013e31828de7e0 - DOI - PMC - PubMed
    1. Cronan MR, Beerman RW, Rosenberg AF, et al. . Macrophage epithelial reprogramming underlies mycobacterial granuloma formation and promotes infection. Immunity. 2016;45(4):861-876. doi:10.1016/j.immuni.2016.09.014 - DOI - PMC - PubMed